Takeda Pharmaceutical, Eisai, and Nippon Chemiphar offeredearly retirement programs over the past year, a Jiho survey revealed. It appears that not all of them are looking at downsizing, however, with some aggressively seeking to “rejuvenate” their employees by replacing ones…
HOME > COMMENTARY
COMMENTARY
- Pharmacology of Aging and Longevity: Looking for Anti-Aging Therapeutics （２）
November 2, 2009
- Pharmacology of Aging and Longevity: Looking for Anti-Aging Therapeutics （１）
November 2, 2009
- How Not to License a Drug into Japan
October 12, 2009
- TOPICS／Abbott Named One of the "Best Places to Launch a Career" by BusinessWeek
October 5, 2009
- NHI Drug Pricing System Reform Becomes Further Unpredictable Following Gov't Change
October 5, 2009
- COMMENTARY／Pharma Industry Watches New DPJ Administration with Both Anticipation and Concerns
September 21, 2009
- COMMENTARY／Will It Be Possible to Eliminate Use of Multiple Antipsychotics in Massive Doses?
September 14, 2009
- COMMENTARY／Establish Solid Criteria for Switching Ethical Drugs to OTC Status
September 14, 2009
- COMMENTARY／Korosho to Embark on Japanese Version of Sentinel Initiative
September 7, 2009
- COMMENTARY／Wholesalers Need to Analyze Causes of Their Failure
August 24, 2009
- COMMENTARY／Hisamitsu Aims at Growth by Fusing Its and Noven's Technologies
August 24, 2009
- COMMENTARY／Permitting MSs to Take MR Cert. Exam Offers New Business Opportunity to Wholesalers
August 3, 2009
- COMMENTARY／Fair Profits Are Essential to Spread Regenerative Medicine
August 3, 2009
- Hitech Drugs Open the Window to the Future- With Special Focus on Development and Marketing -(1)
July 20, 2009
- Hitech Drugs Open the Window to the Future- With Special Focus on Development and Marketing -(2)
July 20, 2009
- COMMENTARY／Global Pharmas Enhance Their Presence in Japan
July 13, 2009
- COMMENTARY／Additional Price Cuts for Long-listed Original Drugs
June 29, 2009
- COMMENTARY／Clinical Applications of ADCs Coming Closer to Reality
June 29, 2009
- SURVEY／RLS Takes Almost Four Years before Being Diagnosed
June 22, 2009
- COMMENTARY／JSHP to Promote Use of Generics
June 8, 2009
ページ
The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
The past month has seen two significant milestones in healthcare price control measures in Japan: The first “off-year” NHI reimbursement price cuts, and release of the first results under Japan’s “cost-effectiveness assessment” system. Both milestones have been anticipated for quite…